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Abstract
Background: Antipsychotic medication is effective for symptomatic treatment in schizophrenia-spectrum disorders.
After symptom remission, continuation of antipsychotic treatment is associated with lower relapse rates and lower
symptom severity compared to dose reduction/discontinuation. Therefore, most guidelines recommend
continuation of treatment with antipsychotic medication for at least 1 year. Recently, however, these guidelines
have been questioned as one study has shown that more patients achieved long-term functional remission in an
early discontinuation condition—a finding that was not replicated in another recently published long-term study.
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Methods/design: The HAMLETT (Handling Antipsychotic Medication Long-term Evaluation of Targeted Treatment)
study is a multicenter pragmatic single-blind randomized controlled trial in two parallel conditions (1:1)
investigating the effects of continuation versus dose-reduction/discontinuation of antipsychotic medication after
remission of a first episode of psychosis (FEP) on personal and social functioning, psychotic symptom severity, and
health-related quality of life. In total 512 participants will be included, aged between 16 and 60 years, in
symptomatic remission from a FEP for 3–6 months, and for whom psychosis was not associated with severe or life-
threatening self-harm or violence. Recruitment will take place at 24 Dutch sites. Patients are randomized (1:1) to:
continuation of antipsychotic medication until at least 1 year after remission (original dose allowing a maximum
reduction of 25%, or another antipsychotic drug in similar dose range); or gradual dose reduction till eventual
discontinuation of antipsychotics according to a tapering schedule. If signs of relapse occur in this arm, medication
dose can be increased again. Measurements are conducted at baseline, at 3, and 6 months post-baseline, and
yearly during a follow-up period of 4 years.
Discussion: The HAMLETT study will offer evidence to guide patients and clinicians regarding questions concerning
optimal treatment duration and when to taper off medication after remission of a FEP. Moreover, it may provide
patient characteristics associated with safe dose reduction with a minimal risk of relapse.
Trial status: Protocol version 1.3, October 2018. The study is active and currently recruiting patients (since
September 2017), with the first 200 participants by the end of 2019. We anticipate completing recruitment in 2022
and final assessments (including follow-up 3.5 years after phase one) in 2026.
Trial registration: European Clinical Trials Database, EudraCT number 2017-002406-12. Registered 7 June 2017.
Keywords: Antipsychotic medication, first episode psychosis, Maintenance, Treatment, Discontinuation, Tapering,
global functioning, Randomized controlled trial
Background
Antipsychotic medication is effective in diminishing se-
verity of psychotic symptoms and in reducing the risk
for psychotic relapse [1]. Most current guidelines state
that individuals with a first episode of psychosis (FEP)
should be offered antipsychotic medication for at least 1
year after remission of psychotic symptoms (National
Institute for Clinical Excellence guidelines, 2014 (UK)
[2]; Early Psychosis Guidelines Writing Group, 2010
(Australia) [3]; Zorgstandaard Psychose, 2017 (the
Netherlands) [4]). Despite the favorable effect of antipsy-
chotics on reducing positive symptoms, patients often
have a strong wish to stop medication after a treatment
duration shorter than 1 year. This wish partly reflects
the negative side effects of antipsychotic medication,
such as weight gain, anhedonia, sedation, sexual dys-
function, and parkinsonism [5]. Therefore, in day-to-day
practice, patients, their relatives, as well as clinicians face
the question: to continue or not to continue?
Discontinuation or maintenance therapy: relapse rates
A meta-analysis including 65 trials has shown that
maintenance therapy of antipsychotic medication after
remission reduced the risk of relapse more than
twofold (i.e., 27% relapse rate with maintenance treat-
ment versus 64% relapse in a year without medica-
tion) [6]. More recently, a systematic review
conducted by Karson and colleagues [7] addressed the
long-term effects and also found that continuation of
antipsychotic medication was more effective than
treatment discontinuation or intermittent/guided dis-
continuation in preventing relapse. However, it is im-
portant to note that most of the summarized trials
were not designed to test continuation versus discon-
tinuation. Alvarez-Jimenez and colleagues [8] specific-
ally reviewed trials that randomized FEP patients to
either dose reduction/discontinuation or maintenance
treatment. They included eight randomized controlled
trials; follow-up time of the included studies varied
between 1 and 2 years. The overall relapse rate was
higher in the dose reduction/discontinuation groups
compared to maintenance treatment. This review was
recently updated by Thompson and colleagues [9] in-
cluding one extra study [10]; their conclusions were
similar as relapse rates were higher in the discontinu-
ation group (53%) versus the maintenance treatment
group (19%) after a follow-up period of 1 to 2 years.
To date, only a few randomized trials have been con-
ducted over a longer follow-up period of more than 2
years. Wunderink and colleagues [11] were the first to
show long-term positive effects of early-course discon-
tinuation of antipsychotic treatment, which may shed a
different light on previous studies with a shorter dur-
ation. While they observed that the relapse rates were
initially higher for the discontinuation strategy (43%)
versus the maintenance condition (21%) after a follow-
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up period of 2 years, the relapse rates were equal after 3
years follow-up [12]. Moreover, after 7 years, dose
reduction/discontinuation patients showed higher func-
tional recovery rates versus patients following mainten-
ance treatment. Recently, Hui et al. [13] reported on
their 10-year follow-up study. Notably, they found
higher rates of poor long-term clinical outcome in the
discontinuation group (39%) compared to the mainten-
ance treatment group (21%). Moreover, relapse was a
significant predictor of 10-year clinical outcome.
Discontinuation versus maintenance therapy: functional
recovery
Looking beyond relapse rates, the Dutch patient
organization Anoiksis argued that the decision of pa-
tients to either continue or discontinue medication
should mainly be based on its proposed impact on func-
tioning in the main domains of everyday life (surveyed
in 2017). In the short term, previous studies have found
no significant difference between maintenance therapy
versus dose-reduction/discontinuation on functional re-
covery [12, 14]. The follow-up of the Wunderink [12]
study demonstrated that, after 7 years, patients in the
original discontinuation condition experienced twice the
functional recovery rate (40.4%) in comparison to those
on maintenance treatment (17.6%) [11]. However, the
recent study by Hui and colleagues [13] also investigat-
ing the effects of early discontinuation on long-term
clinical outcome at 10 years was in strong contrast with
the Wunderink [12] finding, as they reported a higher
risk of poor clinical outcome in the discontinuation
group compared to the maintenance group (respect-
ively 39% versus 21%). Poor clinical outcome was de-
fined by persistent positive symptoms of psychosis,
treatment-resistant psychosis, or death by suicide.
Finally, Tiihonen, Tanskanen, and Taipale [15] ob-
served the risk of treatment failure after discontinu-
ation of antipsychotic treatment in a cohort of 8719
schizophrenia patients, defined as psychiatric re-
hospitalization or death. The lowest risk of treatment
failure was observed in patients treated with anti-
psychotic drugs continuously, followed by patients
who discontinued medication immediately after dis-
charge from hospital treatment. Notably, when anti-
psychotic drugs were discontinued at a later stage,
the risk of treatment failure was even more increased
(possibly explained by changes in dopamine sensitivity
or by confounding by indication).
Discontinuation versus maintenance therapy: emotional
and cognitive functioning
In the context of functional recovery, the impact of (dis)-
continuation on emotional and cognitive functioning
needs to be evaluated. Blockade of the dopamine D2
receptors, the main mediator of efficacy of antipsychotic
medication [16], can produce adverse subjective experi-
ences or neuroleptic dysphoria [17–19], encompassing a
variety of unpleasant subjective changes in arousal,
mood, thinking, and motivation [20]. Severity of these
mental adverse effects depends on individual variability
of sensitivity and proportion of D2 receptors blocked. In-
dividuals with lower baseline dopamine function are at
increased risk for dysphoric responses during treatment
with dopaminergic blocking drugs [20]. With regard to
dosage of antipsychotic medication, most mental adverse
effects occur at D2 receptor occupancy higher than 65–
70% [17]. In addition to dysphoria, dopamine blockade
may reduce functioning by exerting negative effects on
cognition. Dopamine plays an important role in learning
and motivation, as it enables associative learning, espe-
cially of aversive stimuli [21]. Approximately 50% of
men and up to 70% of women report difficulty in con-
centrating or tiredness with the use of antipsychotic
medication [22]. Blockade of this system reduces the
cognitive capacity to learn new associations, which may
hinder study or work [23]. Blockade of the mesolimbic
reward system also reduces motivation and drive, which
can be expected to hamper professional and social suc-
cess [24].
Mental and cognitive adverse effects associated with
higher doses may explain why functional recovery can
improve when patients reduce or discontinue the dose
of their antipsychotic medication. Despite these theoret-
ical expectations, cognitive improvement after continu-
ation of treatment as compared to dose reduction/
discontinuation in patients with FEP has been re-
ported by seven studies, with a sustained effect for up
to 2 years [7]. This may be explained by the deleteri-
ous effects of recurrent psychotic episodes on cogni-
tion [25]. While dopamine blockade may be aversive
for mood and cognition, the effect of a psychotic re-
lapse on both these domains may be even more sub-
stantial, leading to the relatively larger improvement
when maintaining on antipsychotic treatment. How-
ever, an add-on study to the Wunderink et al. [12]
trial found that dose reduction/discontinuation was
associated with more improvements in neurocognitive
functioning in FEP patients 5 months after receiving
remission, compared to those maintaining on second-
generation antipsychotics [26]. Importantly, long-term
effects are still unclear, and more knowledge is
needed on how maintenance therapy and dose reduc-
tion/discontinuation affect emotional and cognitive
functioning in FEP patients.
The current HAMLETT study
Taken together, previous trials comparing dose reduc-
tion/discontinuation versus treatment maintenance
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have indicated that continuation of antipsychotic
medication reduces the risk of psychotic relapse in re-
mitted FEP patients. However, harmful effects may
also be associated with maintenance treatment [27]
and two studies with long-term follow-up have shown
contradictory findings [12, 13]. This makes it difficult
to determine best practices based on the current lit-
erature. Patients, their relatives, as well as clinicians
need to know whether dose reduction is a beneficial
option for them after remission of psychosis or not,
particularly in terms of global functioning, thereby
going beyond symptomatic remission. This knowledge
is needed to inform decisions concerning when to
taper off antipsychotic medication and to evaluate
which factors moderate safe dose reduction. Here we
will describe the rationale, design, and methods of a
pragmatic single blind randomized controlled trial in
the Netherlands: the HAMLETT study (Handling
Antipsychotic Medication: Long-term Evaluation of
Targeted Treatment).
Methods/design
This paper is written in line with the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) 2013 explanation and elaboration [28], see Add-
itional file 2.
Aim and objectives
The aim of the HAMLETT study is to investigate
whether long-term (i.e., 4 years) functional and symp-
tomatic recovery of patients remitted from a FEP is im-
proved when they gradually reduce their antipsychotic
medication 3 to 6 months after remission of psychotic
symptoms, or when they continue to use medication for
at least 1 year after remission. The following research
questions will be addressed:
1. Do patients in the dose-reduction/discontinuation
condition achieve a higher level of global function-
ing compared to the maintenance condition?
2. Does subjective wellbeing, somatic health (including
metabolic syndrome), relapse rates, and
hospitalizations differ between the dose-reduction/
discontinuation condition and the continuation
condition?
3. Do rates of self-harm (aggressive incidents, suicide
attempts, and suicide) differ between the mainten-
ance treatment and the dose-reduction/discontinu-
ation condition?
4. Which baseline or follow-up characteristics are as-
sociated with successful discontinuation of anti-
psychotic medication?
In addition, health-economic evaluation and prognos-
tic modeling will be conducted:
1. To assess the incremental cost-effectiveness (cost
per functional recovery) of dose reduction and dis-
continuation relative to maintenance
2. To assess incremental cost-utility (cost per quality
adjusted life year (QALY)) of dose reduction and
discontinuation relative to maintenance
3. To identify patient profiles that predict the greatest
net (monetary) benefits after dose reduction/
discontinuation
4. To calculate budget impacts of scaling up dose
reduction and discontinuation strategies, should
these strategies be proven acceptable, effective, and
cost-effective
Trial design and setting
HAMLETT is a pragmatic single-blind randomized con-
trolled trial of continuation versus discontinuation/dose
reduction of antipsychotic medication in patients remit-
ted after a FEP. To provide clear, clinically relevant guid-
ance for clinicians and patients on short- and long-term
benefits and disadvantages of continuation or discon-
tinuation/dose reduction of antipsychotic treatment, the
study population and their treatment should resemble
the general clinical situation as much as possible.
Recruitment will take place at 24 Dutch sites.
The study is divided in two phases: (1) an experimen-
tal phase of 6 months, (2) a follow-up phase of 3.5 years.
The experimental phase consists of a screening visit (− 3
to 0 months before participating), a baseline visit, a mid-
term visit (at 3 months post-baseline), and a close-out
visit (6 months post-baseline). The follow-up phase con-
sists of four visits (i.e., at 12, 24, 36, and 48 months post
baseline). Study examinations scheduled in the course of
the study are listed in Table 1 (these are described in
more detail in Appendix 2).
Study population and eligibility criteria
Study population
A total of 512 patients will be included with a first epi-
sode of schizophrenia, schizoaffective disorder, schizo-
phreniform disorder, brief psychotic disorder, delusional
disorder, substance/medication-induced psychotic dis-
order, or those classified as Unspecified Schizophrenia
Spectrum and Other Psychotic Disorders (DSM-5, or as
described in the International Classification of Diseases-
10), who are in remission for 3–6 months. Patients will
be recruited from both inpatient and outpatient settings
in 24 health care centers throughout the Netherlands.
Randomization (1:1) will be stratified according to the
collaborating centers (see Appendix 1 for a list of study
sites and health care centers).
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Inclusion criteria
1. The participant has had a first episode of psychosis
and uses antipsychotic medication.
2. Psychotic symptoms are in remission for 3-6 months.
3. Age 16-55 years.
4. The participant understands the study and is able
to provide written informed consent.
5. HAMLETT is the only medical-scientific medica-
tion study in which the patient participates.
6. Sufficient knowledge and ability of the Dutch language.
Exclusion criteria
1. Dangerous or harmful behavior (i.e., behavior with a
risk of severe physical injury, or actual physical injury
inflicted, to self or others) occurred during FEP
2. Coercive treatment with antipsychotic medication
during FEP (based on a judicial ruling)
Patient withdrawal
Subjects can leave the study at any time for any reason if
they wish to do so, without any consequences. The clin-
ician or investigator can decide to withdraw a subject
from the study for urgent medical reasons.
Interventions
Continuation condition Patients in the continuation
condition are treated according to Dutch guidelines [4, 29],
which recommend at least 1-year continuation after remis-
sion. During this year, medication will be kept within the
same range, allowing a 25% dose reduction; increase of dos-
age is not restricted. After that first year, a shared decision
Table 1 Overview of assessments during the trial
Abbreviations: BACS Brief Assessment of Cognition in Schizophrenia, BARS Barnes Akathisia Rating Scale, BeHapp Smartphone application, CASH Comprehensive
Assessment of Symptoms and History, CTQ-SF Childhood Trauma Questionnaire-Short Form Multidimensional Scale of Perceived Social Support, EMA Ecological
Momentary Assessments, GAF Global Assessment of Functioning, MINI-Screener Mini-International Neuropsychiatric Interview Screener, MSPSS Multidimensional
Scale of Perceived Social Support, PANSS Positive And Negative Symptom Scale, SHRS St. Hans Rating Scale, WHO-DAS 2.0 World Health Organisation Disability
Assessment Schedule
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is made for further continuation or gradual discontinuation
based on the patient’s motivation and the clinical situation
(in case of discontinuation, the tapering schedule as de-
scribed below can be used). Patients and their treatment
team may diverge from this regimen for several reasons,
such as intolerable side effects, insufficient efficacy, or the
wishes of the patient. In such cases, the patients will remain
in the study.
Discontinuation/dose reduction condition Discon-
tinuation schedules have been prepared by the study
team for common antipsychotic drugs available in the
Netherlands (including haloperidol, risperidone, quetia-
pine, olanzapine, clozapine, and aripiprazole; Additional
file 1). Discontinuation schedules were constructed on
the following principles: smooth and gradual regular
lowering of the serum levels of antipsychotic medication.
Since we could not use tapering strips, we needed to di-
minish antipsychotic medication depending on availabil-
ity of different dosages and the possibility to divide
tablets. Treating physicians prescribe the tapering sched-
ule that fits the patient’s type and dose of baseline medi-
cation, yet details can be tailored in collaboration with
the patient and important relatives. When dose reduc-
tion is successful, patients can discontinue their medica-
tion completely. Duration of the discontinuation period
depends on the starting dose (see Additional file 1). The
average duration until complete discontinuation is 3
months.
In a letter for the treating physician, the study team
provides recommendations on discontinuation schedules
for the various antipsychotics used (Additional file 1)
and provides a diary to be used by participants during
the tapering process, providing practical advice and a
questionnaire focusing on possible early warning signs
for psychotic relapse. A signaling plan describing early
warning signs and a plan of action is made with the
treating physician prior to tapering off medication. Pa-
tients can find early warning signs (e.g., social with-
drawal, sleep disturbances) in a booklet provided to the
patient at the beginning of the study, and they are also
noted by the patient/caregiver/family/relatives of the pa-
tient. Patients and their treatment team may opt to halt
discontinuation at any time or dose when (subclinical)
symptoms reappear, in which case participants will re-
main in the study, even though further discontinuation
is not deemed possible. In case early warning signs
occur, further tapering off of antipsychotic medication
will be halted until early warning signs disappear. Stress
reduction will be advised. When early warning signs dis-
appear, tapering off antipsychotic medication can be re-
sumed. When early warning signs become more severe,
the dosage of antipsychotic medication will be increased
to one level higher (in other words, back to the former
step) of the tapering off scheme. When psychotic symp-
toms occur, treatment with antipsychotic medication
will be restarted in the dose that patients used when the




Personal and social functioning will be evaluated using
the WHO-DAS 2.0 disability scale [30]. This question-
naire will be administered as an interview and consists
of 36 items covering six domains of functioning in
everyday life: cognition (understanding and communi-
cating), mobility (moving and getting around), self-care
(hygiene, dressing, eating, and staying alone), getting
along (interacting with other people), life activities (do-
mestic responsibilities, leisure, work, and school), and
participation (joining in community activities).
Secondary outcomes—cognitive measures
Neurocognitive functioning will be assessed with the
Brief Assessment of Cognition in Schizophrenia [31]
(BACS). The BACS consists of the following domains:
1. Verbal memory: List learning
2. Working memory: Digit sequencing task
3. Motor speed: Token motor task
4. Verbal fluency: Category instances
5. Verbal fluency: Controlled oral work association
test
6. Attention and speed of information processing:
Symbol coding
7. Executive functions: Tower of London
Clinical outcomes
1. General functioning will also be evaluated using the
Global Assessment of Functioning scale [32] (GAF).
2. Psychotic symptom severity will be measured with
the Positive and Negative Symptom Scale [33]
(PANSS).
3. Quality adjusted life years (QALYs) will be
measured using the EuroQoL [34] (EQ-5D-5 L).
4. The presence and severity of movement disorders
will be evaluated using St. Hans Rating Scale [35]
(SHRS) and Barnes Akathisia Rating Scale [36]
(BARS).
5. Personal recovery with a special focus on hope and
self-determination will be assessed using the Recov-
ery Assessment Scale [37] (RAS).
6. Other study parameters are psychotic relapse,
rehospitalization, somatic health, obesity,
parkinsonian side effects, depressed mood or
anxiety, clinical variables (e.g., medication use, time
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spent with treatment team, premorbid
adjustment, side effects), somatic health will be
evaluated by measuring weight, height, blood
pressure, waist circumference, and body mass
index (BMI), and safety data will be evaluated by
comparing incidences (number and percentage of
subjects) of key serious adverse events (SAEs)
between both groups (e.g., relapse and
hospitalizations; Appendix 3).
Baseline characteristics
1. Diagnostic information and (socio)demographics
will be collected using the Comprehensive
Assessment of Symptoms and History [38]
(CASH).
2. During each occasion, the following blood
levels were determined: high density lipoprotein
cholesterol (HDL-C) and fasting glucose,
cholesterol, LDL, C-reactive protein (CRP),
blood levels of the antipsychotic used. DNA
isolation and aliquotation of the serum will also
be done.
3. Experience of childhood trauma will be assessed at
baseline using the Childhood Trauma
Questionnaire–Short Form [39] (CTQ-SF).
Speech production
Antipsychotic medication is known to interact with re-
ceptors in language-related areas in the brain [40].
Therefore, antipsychotics are likely to influence language
production in patients with a psychotic disorder. By
analyzing phonetic, syntactic, and semantic aspects of re-
corded spoken language using a semi-structured inter-
view at different time points during the study, we aim to
analyze the effect of antipsychotic medication on lan-
guage production.
Optional studies
Ecological momentary assessments and BeHapp
Two embedded ecological momentary assessment
(EMA) [41] studies which use smartphone diary apps
will be performed. In study 1, 88 patients be will
assessed ten times a day at semi-random moments dur-
ing 7 days to measure momentary positive/negative
affect, paranoia, hallucinations, social company, and so-
cial functioning and activities. EMA will be completed at
Fig. 1 An overview of the procedure when early warning signs or psychotic symptoms reappear while tapering off medication. EWS early
warning signs
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baseline, 6 months, and 1, 2, 3, and 4 years follow-up.
For study 2, a sub-sample of 30 patients will
complete an intensive series of EMA during 16 con-
secutive weeks in order to analyze within individuals
to which degree early changes in the dynamic system
of mental states predict future clinical change. Fur-
thermore, we also ask participants to install the
‘BeHapp’ smartphone application [42], in which sev-
eral aspects of daily life concerning social behavior
will be measured passively. The application will con-
tinuously monitor frequency and duration of smart-
phone usage (but not content), as well as information
on Bluetooth connections, WiFi, and GPS locations.
For a detailed description, see Appendix 3.
Magnetic resonance imaging outcome measures
Differences in brain volume between continuation and
discontinuation of antipsychotic medication will be in-
vestigated by means of structural Magnetic Resonance
Imaging (sMRI). Specifically, we will scan 150 patients at
baseline, before (dis)continuation and after 12-month
follow-up. We will evaluate the effects of antipsychotics
on total brain volume and on specific structures such as
hippocampus, thalamus, caudate, and parietal and pre-
frontal cortex, including effects of type of medication
and gender. Potential brain volume loss within individ-
uals will be investigated by comparing the two scans
with a 12-month follow-up.
Positron emission tomography
Discontinuation of antipsychotic medication after the
use of these drugs for several months may render pa-
tients especially vulnerable to relapse. The potential
mechanism behind this vulnerability could be increased
density of postsynaptic dopamine D2 receptors in the
striatum. We will investigate the presence of dopamin-
ergic abnormalities, as measured with [11C] raclopride,
in relation to antipsychotic medication discontinuation
in 30 patients remitted after a FEP. We will scan patients
1–7 days after discontinuation and 6–8 weeks after the
first scan.
Resource use
Patients’ health care usage and productivity losses will
be measured with the Trimbos and iMTA Cost ques-
tionnaire associated with Psychiatric illness [43] (TiC-P),
which is the most commonly used health service receipt
interview in the Netherlands. This is required to com-
pute heath care costs (including intervention costs), the
patients’ out of pocket costs for making round trips to
health services, the opportunity costs of relatives and
friends when offering care to the patient, and to assess
the costs stemming from productivity losses when
patients are on sick leave (absenteeism) and when they
cut back on work while at work (presenteeism).
Safety measures
After inclusion in the study, a personal patient profile in
which individual early warning signs of impending re-
lapse are described will be created. These signs are the
individual prodromal signs a patient experienced before
their first psychotic episode. Patients and relatives will
be instructed to contact professional caregivers in case
of occurrence of early warning signs. Treatment will be
modified in case of occurrence of early warning signs or
other indications of clinical worsening. Documentation
of occurrence and severity of signs and symptoms and
treatment modification will be assessed during each visit.
Patients and their involved relatives will be advised on
the tapering off or continuation scheme (depending on
the condition and depending on occurrence of early
warning signs or psychotic relapse). Adverse events
(AEs) are defined as any substantial undesirable experi-
ence occurring to a subject during the study (including a
psychotic relapse without hospitalization), whether or
not considered related to treatment allocation. All AEs
and SAEs reported spontaneously by the subject or ob-
served by the clinician or research staff will be recorded,
according to the protocol, in the electronic case report
form (eCRF).
Sample size
This study will use WHO-DAS 2.0 [30] personal and so-
cial functioning as a continuous primary outcome and is
powered to detect a standardized mean effect of at least
d = 0.33 (minimal effect deemed clinically relevant by
Lipsey and Wilson [44]). We assume a clustering effect
in the data corresponding to an intra-class correlation
coefficient of 0.05. Tests will be conducted with alpha =
0.05 (two-sided) and a power (1-beta) = 0.80. This
requires 230 participants per arm. Given the long
follow-up, we expect dropout. Although an intention-to-
treat analysis is robust against moderate dropout, we
aim to include an extra 10% to compensate for dropout.
Therefore, we aim to randomize 230/(1 − 0.10) = 256 per
arm, or 512 patients in total.
Recruitment and allocation
Recruitment
In total, 24 different specialized health care centers col-
laborate in the HAMLETT study. Each participating
center has a principal investigator (PI) to promote and
implement the study within their organization. Each site
also has a (part-time) dedicated includer (DI; i.e., who
preferably is a member of the clinical staff, for instance a
nurse) with the task of facilitating inclusion and assisting
clinicians by selecting and inviting potential participants.
Begemann et al. Trials          (2020) 21:147 Page 8 of 19
Allocation
The randomization will take place after the baseline visit
and is conducted by unblinded members of the research
team. A web-based application will be used (random.
org/sealedenvelipe.com), randomization is stratified for
treatment according to the collaborating centers, with a
1:1 allocation ratio. The randomization outcome is com-
municated directly to the treating physician, together
with a suggestion for discontinuation/dose reduction
schedule (Table 1) if their patient is randomized to this
group. The general practitioner and pharmacist of the
patient are also informed.
Blinding
This study will be single-blind: only the assessor who
performs the assessments and conducts the interviews is
blind for the treatment condition of the patient. When
blinding is broken, for example, because a patient com-
municates about his medication use or discontinuation,
the assessor is replaced by another rater who is still
blind. Clinicians and patients are not blinded.
Data collection methods and management
Patient visits and examinations specified per visit can be
found in Table 1; these are described in more detail in
Appendix 2. Participants in the HAMLETT study will
receive a gift voucher at each visit, in each study condi-
tion (as approved by the ethics committee of the Univer-
sity Medical Center Groningen). Data collection forms
are on paper and entered into an eCRF. To ensure data
quality, assessors are comprehensively informed and
trained regarding Good Clinical Practice (GCP). Experts
train users in the proper conduct of the WHO-DAS-2.0
[30], BACS [32], PANSS [33], CASH [38] interview,
movement disorder scales (SHRS [35], BARS [36]), and
cognitive testing. In addition, the team of assessors have
biannual meetings every 6 months during which inter-
rater reliability is assessed, new assessors are trained,
supervision is given, and protocol adherence is checked.
Privacy laws and regulations will be adhered to dur-
ing the length of the study. The collection and process-
ing of participants’ personal information will be limited
to what is necessary to ensure the study’s scientific
practicability, the evaluation of efficacy, adherence, side
effects, and the investigational product’s safety. Infor-
mation collected about participants during this clinical
investigation will be treated confidentially. The investi-
gator or her co-workers will collect data and transfer
them without recording the patient’s name or date of
birth. Instead, data will be coded with a participant
identification number.
Only authorized personnel will have access to the
identification key. The source documents will be kept
in a locked filing cabinet with access limited to
research personnel. In accordance with national laws
and guidelines and the specifications of the ICH-GCP
guidelines, the investigators are obligated to archive
all documents pertaining to the study for the legally
required time period.
The acquired data and examination results will be en-
tered into an eCRF that is accessible via the internet.
Investigators will receive personal user names and pass-
words for this purpose, and data will be encrypted for
transfer. It will be agreed before the start of the study as
to which documents serve as source documents for all
data entered into the eCRF.
Collaboration with important others
The HAMLETT study is performed in close collabor-
ation with MIND Ypsilon, a Dutch organization of rela-
tives and carers of people with vulnerability to psychosis,
and Anoiksis, a Dutch patient organization. When a
participant is enrolled in the study, he/she is invited
to bring a friend, parent, or other relative to the ap-
pointments in order to receive information as well.
During the phase in which medication is tapered off,
participants are encouraged to engage an important
other in this process (this can be a parent, partner,
sibling, or close friend). Both the participant and his/
her close associate are given a booklet which contains
information about potential risks and gains associated
with tapering off medication. This also includes a list
of questions to assess early warning signs and signs
of relapse. Telephone numbers are supplied to indi-




Research questions 1 to 4 will be tested using general-
ized linear mixed modeling for continuous outcomes
(WHO-DAS 2.0 functioning as a continuous outcome),
logistic models for binary outcomes (WHO-DAS 2.0 re-
covery), and Poisson models for tallies (0, 1, …, N) of
psychotic relapses and hospitalizations. The models will
take into account the clustered data structure of re-
peated measures within each patient, and patients being
nested in treatment centers. Data will be analyzed ac-
cording to the intention to treat principle. These ana-
lyses will be conducted for both primary outcome and
secondary outcomes. The tests will be conducted at α ≤
0.05 (two-tailed), and reported as stipulated by the
CONSORT statement.
Health-economic evaluation
A cost-utility analysis (CUA) and cost-effectiveness ana-
lysis (CEA) will be conducted alongside the study with
quality adjusted life years (QALYs) gains and WHO-
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DAS 2.0 functional recovery as the main outcomes, re-
spectively. Costs will be computed by multiplication of
health care units (visits, sessions, contacts, hospital days)
by their appropriate standard cost price. Missing cost
and outcome data will be imputed using multiple imput-
ation for intention-to-treat (ITT) analysis. Since the
study’s follow-up measurements exceed 1 year, both
costs and effects will be discounted by 4% and 1.5%, re-
spectively. Cumulative costs and QALY health gains over
the study’s follow-up period will be computed with the
area under the curve method. The incremental cost-
effectiveness ratio (ICER) will be computed to obtain the
incremental costs per WHO-DAS 2.0 functional recov-
ery and the incremental costs per EQ-5D-5 L QALY
gained. Stochastic uncertainty will be handled using
2500 non-parametric bootstraps and by plotting the sim-
ulated ICERs on the ICER plane. For decision-making
purposes, the ICER acceptability curve will be graphed
for various willingness-to-pay (WTP) ceilings for making
judgments whether the dose-reduction/discontinuation
intervention offers good value for money relative to
maintenance. One-way sensitivity analyses directed at
uncertainty in the main cost drivers (e.g., costs of
hospital re-admissions after psychotic relapse) and out-
comes (e.g., under different imputations) will be per-
formed to assess the robustness of our findings. Both the
analysis and reporting of the research findings will con-
form to the CHEERS statement [45, 46].
Prognostic modeling
Prognostic modeling will be used to identify patient
characteristics that predict (1) successful WHO-DAS 2.0
functional recovery, (2) successful discontinuation with-
out psychotic relapses, and (3) greater net-benefits
(QALY gains valued in euros minus health care costs).
Prognostic modeling will be conducted in R with a suite
of models (logistic regression, K-nearest neighbors, clas-
sification tree, random forests, gradient boosting, and
support vector machine) and will be driven by the fol-
lowing expectations:
1. Patients with longer duration of untreated
psychosis, comorbid drug abuse, male gender, lower
education and earlier onset of psychosis will carry a
poorer prognosis.
2. Dose-reduction/discontinuation will be more
successful in patients who have used lower doses of
medication, or have used medication with relatively
low D2 receptor affinity (clozapine, quetiapine, and
olanzapine).
3. Personal and social functioning will be superior in
patients who participated in psychosocial
interventions such as cognitive behavioral treatment
(CBT) and individual placement and support (IPS).
4. Psychotic relapse rates after discontinuation will be
lower in patients who received CBT and IPS.
In short, these analyses will address the question of
what works best for whom, and may support treatment
decisions such as which patients are best referred to
dose-reduction and discontinuation.
Interim analysis
Interim analyses are planned to assess if one of the
trial’s conditions (either discontinuation or continu-
ation) is associated with markedly inferior outcomes.
Interim analyses will be performed after 1 and 3
years by an independent statistician. Dr. Klaas
Wardenaar (University Medical Center Groningen,
Faculty of Medical Sciences, the Netherlands) kindly
agreed to assume this role. The interim analyses will
be conducted for the primary efficacy end point of
the study obtained from patients in the target popu-
lation. The statistical analyses will be carried out at
the two-sided overall alpha-level of 0.05. The type I
error boundaries for statistical significance will be
adjusted for multiple comparisons (i.e., total number
of analyses = 3). A design-based error spending func-
tion using the O’Brien-Fleming boundaries will be
applied [47]. The O’Brien-Fleming plan allocates the
alpha error conservatively across the interim and
final analyses in the study. At the first interim ana-
lysis, a two-sided p value will be declared significant
if it is less than 0.0021; at the second interim ana-
lysis, the respective alpha error boundary will be
0.0105. At the final analysis, the two-sided p value
will be declared significant if it is less than 0.025.
Based on the outcome at the interim stage (i.e., if
p < 0.0021 or p < 0.0105, for the two interim analyses,
respectively), the study can be stopped for over-
whelming evidence of group difference.
Data monitoring
Medical ethical review board
Ethics approval covering all participating sites was ob-
tained from the research and ethics committee of the
University Medical Center Groningen, the Netherlands,
protocol number NL 62202.042.17.
Declaration of Helsinki
The study will be conducted in accordance with this
protocol as well as the principles of the Declaration of
Helsinki (64th WMA general assembly; October 2013).
Information collected about participants during this clin-
ical investigation will be treated confidentially.
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Patient safety
The study team can at all times be contacted at the tele-
phone number provided on the contact card and letters
that the patients receive during the study. The patients’
day-to-day care is the responsibility of the treating
physician.
The sponsor/investigator has a liability insurance
which is in accordance with article 7, subsection 6 of the
WMO. The sponsor (also) has insurance for participants
in accordance with the legal requirements in the
Netherlands (Article 7 WMO and the Measure regard-
ing Compulsory Insurance for Clinical Research in
Humans of 23 June 2003). This insurance provides cover
for damage to research subjects through injury or death
caused by the study.
1. €650,000.-- (i.e., four hundred and fifty thousand
euro) for death or injury for each subject who
participates in the research;
2. €5,000,000.-- (i.e., three million five hundred
thousand euro) for death or injury for all subjects
who participate in the research;
3. €7,500,000.-- (i.e., five million euro) for the total
damage incurred by the organization for all damage
disclosed by scientific research for the Sponsor as
‘verrichter’ in the meaning of said Act in each year
of insurance coverage.
The insurance applies to damage that becomes appar-
ent during the study or within 4 years after the end of
the study.
Amendments
A “substantial amendment” is defined as an amendment
to the terms of the ERB application, or to the protocol
or any other supporting documentation, that is likely to
affect to a significant degree:
 The safety or physical or mental integrity of the
subjects of the trial
 The scientific value of the trial
 The conduct or management of the trial, or
 The quality or safety of any intervention used in the
trial
All substantial amendments will be submitted for ap-
proval to the ERB and to the competent authority. For
non-substantial amendments, only a notification will be
sent to the accredited ERB, which will be recorded and
filed by the sponsor.
Public disclosure and publication policy
The results of the study will be submitted for publication
in an international peer-reviewed journal adhering to
applicable privacy laws and regulations. Publication
strategy will be determined by the principal investigator.
No treatment group information will be made available
until after study completion.
Discussion
The HAMLETT study investigates the effects of con-
tinuation versusdose-reduction/discontinuation of anti-
psychotic medication after remission of FEP on personal
and social functioning, psychotic symptom severity,
health-related quality of life, and cognitive functioning,
amongst a range of other relevant outcomes. Many stud-
ies comparing maintenance treatment with dose reduc-
tion/discontinuation have consistently shown that dose
reduction/discontinuation increases the risk of psychotic
relapse in remitted FEP patients [7–9]. Notably, relapse
may be associated with antipsychotic treatment resist-
ance in schizophrenia. A recent study by Takeuchi et al.
[48] suggests a reduced and/or delayed antipsychotic
treatment response in the face of relapse following ef-
fective treatment of first episode schizophrenia. Yet, the
first study with a long follow-up time by Wunderink and
colleagues reported better outcomes after 7 years with
early discontinuation in terms of symptomatic and func-
tional remission compared to maintenance treatment
[11]. The recent study conducted by Hui and colleagues
[13] could not replicate this finding, as they found a
higher risk of poor clinical outcome in the discontinu-
ation group compared to the maintenance group when
evaluating long-term clinical outcome at 10 years. This
underlines the importance of additional long-term co-
horts to systematically investigate the effects of the two
strategies on different outcomes. HAMLETT is a long-
term, well-powered study which is conducted and sup-
ported in the majority of Dutch early psychosis treat-
ment units.
Currently, similar trials are being conducted: the
TAILOR trial [49] (Denmark), the RADAR study (re-
search into antipsychotic discontinuation and reduction;
UK), the reduce trial [50] (Australia), and “A Guided
Dose Reduction Trial for Patients with Remitted Psych-
osis” [51] (Taiwan).
Strengths and limitations of a pragmatic trial
The HAMLETT study is aimed to be the largest random-
ized controlled trial yet reported that investigates the ef-
fects of maintenance treatment versus dose reduction/
discontinuation for FEP. HAMLETT is a pragmatic trial,
with the population and their treatment resembling the
general clinical situation as much as possible to increase
ecological validity and also to pave the way to future im-
plementation. We opted for this design as this study aims
to provide clear guidance for clinicians and patients on
short- and long-term benefits and disadvantages of
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maintenance treatment and dose-reduction/discontinu-
ation of antipsychotic treatment. The naturalistic set-up of
the study has several consequences. First, we kept the ex-
clusion criteria as few as possible. Only when the safety of
the participant is at risk will exclusion follow. Patients
with, for example, comorbidity and drug- and alcohol
abuse will be able to participate, which leads to a hetero-
geneous sample reflecting clinical practice. Second, to ad-
dress the issue of selection bias, all FEP patients eligible
for the study are registered by the early psychosis treat-
ment units. Data are collected on patients who do not
wish to participate in the study (e.g., reason not to partici-
pate, age, and gender). Third, patients can start the trial
using any type of frequently prescribed antipsychotic drug
at any dose (within safety ranges). Fourth, to prevent the
average dose in the maintenance arm and the dose reduc-
tion/discontinuation arm differing too much from each
other, we instruct physicians to not reduce the dose by
more than 25%. Fifth, clinicians and patients are informed
on the allocated condition as they should be attentive to
early warning signs for relapse; researchers are blinded.
Lastly, research suggests that 64% of patients discontinu-
ing medication will relapse [6], which could be quite a
substantial number in our large sample. However, we ex-
pect the relapse rate to be lower in our study as a tapering
schedule is provided by which patients will gradually re-
duce dose over the course of 3–6months; when this is
successful, patients could discontinue completely. When
early warning signs are present, the dose can be increased.
This way, those who respond well to discontinuation may
go on to discontinue completely. The dose of the patients
that do require antipsychotic treatment can be reduced as
much as possible to remain symptom free.
Appendix 1
List of study sites and collaborating centers
1) Universitair Medisch Centrum Groningen, (the
“Coordinator”) / Lentis
2) Academisch Medisch Centrum Amsterdam
3) Universitair Medisch Centrum Utrecht
4) Mondriaan / Universiteit Maastricht
5) TRIMBOS instituut
6) Geestelijke Gezondheidszorg Rivierduinen
7) Arkin
8) Geestelijke Gezondheidszorg Ingeest
9) Geestelijke Gezondheidszorg Eindhoven
10) Altrecht
11) Parnassia Groep
12) Reinier van Arkel stichting
13) Geestelijke Gezondheidszorg NoordHollandNoord
14) Yulius




19) Geestelijke Gezondheidszorg Drenthe
20) Delta
21) Pro Persona
22) Geestelijke Gezondheidszorg Centraal
23) Vincent van Gogh




In each of the 23 participating centers, a local dedicated
includer (DI) appointed by the HAMLETT study pro-
vides information to the patient and when possible his
or her relatives (the information letter including the in-
formed consent form, and the short information bro-
chure). The patient and his or her relatives are given
two weeks (or longer if needed) to consider participa-
tion. A second appointment is made (vis a vis) in which
extra questions can be answered and in which oral and
written information is provided. Additional questions
are answered and if the patient opts to participate, the
informed consent is signed by both the patient and the
DI or a member of the central study team. Patients who
are thought to meet the inclusion criteria are
approached, their treating physician will be notified. The
treating physician decides if the patient is able to make a
well-informed decision. For participants under the age of
18, both parents will be asked to write an assent in
addition to the patient’s consent. Before signing of the
informed consent form, no other study procedures will
be executed, the DI arranges a first visit with the central
study team.
Screening visit
Patients will be screened for eligibility to the study, after
informed consent is completed. Diagnosis will be
checked using the CASH [38] and using the MINI
Screener (developed at the department of Psychiatry,
UMC Groningen). Several demographical and clinical
variables will be assessed, including date of birth, sex,
educational level, zip code, living alone/together, profes-
sion, prior psychiatric disorders, date of diagnosis
(CASH), premorbid functioning (PAS) and duration of
untreated psychosis (retrospectively, as defined by fulfill-
ing a score of ≥4 on one of the positive items of the
PANSS during at least one whole day, until start of anti-
psychotic medication (adapted from Marshall et al. [52]).
Medication use (including antipsychotic use, hormonal
contraception and other medication) will be evaluated,
in addition to side effects and subjective reactions to
these medications (SRA [53], SWN [54]). Physical health
will be checked in a standard physical examination
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(height, weight, waist circumference, Body Mass Index,
blood pressure, pulse, EPS), in addition to medical
history.
Baseline visit
At baseline, the patient will be randomized. Blood sam-
ples will be taken and substance abuse will be measured
using the appropriate section of the CASH. The use of
concomitant medication and medical conditions/ad-
verse events will be recorded. In addition, the standard
rating scales will be used for the first time, including
primary and secondary outcomes (see below for details
of these scales).
Study visits: V3 (3 months post-baseline) + V4 (6 months
post-baseline)
The visits of phase I are scheduled three and six months
after baseline. Some flexibility is allowed, as visits can be
performed within a range of +/− three weeks. Visits will
consist of all rating scales, blood samples and a personal
interview.
Follow-up visits
Follow-up visits are scheduled after the discontinuation
phase is completed, to assess the current status of the
patient after that part of the study. There will be four
annual visits, the first scheduled 6months after comple-
tion of phase 1 (thus one year after baseline), the others
with intervals of one year (+/− three weeks).
Appendix 3
Rating scales
 The World Health Organization’s Disability
Assessment Schedule [30] (WHO-DAS 2.0). The
WHO-DAS 2.0 assesses disability in individuals
irrespective of diagnosis across multiple life domains.
We will use the interview version consisting of 36
items.
 Side effects experienced by the use of mental health
medications as assessed by the:
The Subjective Wellbeing under Neuroleptics
[53] (SWN): self-assessment scale of the subjective
experience of patients during treatment with neu-
roleptics. The 20-item SWN scale has an internal
consistency of 0.93 and the subscale consistencies
ranged from 0.70 to 0.80. Test–retest reliabilities
are observed of r = 0.70. Confirmatory factor ana-
lysis replicated the presence of a higher-order fac-
tor (general well-being) and five first-order factors
(mental functioning, physical functioning, social
integration, emotional regulation, and self-
control).
The Subjective Reaction on Antipsychotics [53]
(SRA) is a 73-item rating scale and consists of ten
scales. Nine scales measure unpleasant effects:
weight gain, sexual anhedonia, sedation, affective
flattening, EPS, reduced sociability, increased sleep
and total unpleasant effects. The last scale added
the unpleasant scales, including the remaining
items. The recovery scale measures the enjoyable
responses attributed to the antipsychotics.
 Internalized Stigma of Mental Illness [55] (ISMI).
Sub scales: alienation, stereotype endorsement,
discrimination experience, social withdrawal and
stigma resistance. Good internal consistency, test-
retest reliability and construct validity.
 Self-esteem Rating Scale- Short form [56] (SERS-S)
 Psychosis Attachment Measure [57] (PAM) is a 16-
item self-rating scale measuring attachment anxiety
and attachment avoidance. This may be an import-
ant predictor of symptoms, interpersonal problems
and difficulties in therapeutic relationships over and
above severity of illness.
 Positive and Negative Syndrome Scale [33] (PANSS):
this is a 30-item rating scale designed to measure se-
verity of psychopathology in adult patients with
schizophrenia. Five components have been reported:
positive, negative, depression, agitation-excitement,
and disorganisation.
 Global functioning will be assessed using the GAF
questionnaire [32].
 The Premorbid Adjustment Scale [58] (PAS) is a
rating scale about five domains of functioning:
sociability, peer relationships, scholastic performance,
adaptation to school and social-sexual aspects. It
covers two life periods: up to 12 and 12 to 16.
 The Recovery Assessment Scale [37] (RAS): this is a
30-item rating scale designed to measure recovery.
 The Multidimensional Scale of Perceived Social
Support [59] (MSPSS) is a 12-item instrument that
measures perceived social support. Four scales have
been reported: significant other, family, friends and
total scale.
 Aggressive and suicidal behavior will be evaluated
using a self-composed list of self-report questions
(developed at the department of Psychiatry, UMC
Utrecht).
 Cigarette, alcohol and drug abuse (as assessed with
the alcohol and drug section of the CASH [38] and
the WHO assist [60].
 The MINI-Screener is a self-report questionnaire
and consists of fife sections: generalized anxiety dis-
order, panic disorder, social anxiety disorder, obses-
sive compulsive disorder and post-traumatic stress
disorder (developed at the department of Psychiatry,
UMC Groningen).
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 Childhood trauma will be evaluated by asking
subjects to fill-in a retrospective self-report ques-
tionnaire, the Childhood Trauma Questionnaire-
Short Form [39] (CTQ-SF).
 Language production will be assessed by an
automatic analysis of spoken language. Patients will
be asked to talk for approximately five minutes, with
a maximum of ten minutes. The recordings will be
automatically parsed and annotated using computer
learning language systems.
Cognitive assessment
Neurocognitive functioning will be assessed with the
Brief Assessment of Cognition [31] (BACS) and the
Stroop task [61]. The BACS is derived from larger
neuropsychological batteries and provides a valid esti-
mate of general cognitive ability. The BACS consists of
the following seven subtasks:
 Verbal memory - List learning: Patients are
presented with 15 words and then asked to recall as
many as possible, which will be repeated five times.
Measure: number of words recalled per trial, in any
order.
 Working memory - digit sequencing task: Patients are
presented with clusters of numbers of increasing
length and are asked to tell them in order from
lowest to the highest. Measure: number of correct
responses.
 Motor speed - Token motor task: Patient are given
100 tokens and are asked to place them in a
container as quickly as possible. Measure: number of
tokens correctly placed into the container.
 Verbal fluency - Category instances: Patients are
asked to name as many words in a certain category
in 60 s (supermarket items, tools). Measure: number
of unique and appropriate answers per category.
 Verbal fluency - Controlled oral word association
test: Patients are asked to generate as many words as
possible that begin with a given letter in 60 s.
Measure: number of unique and appropriate
answers per category.
 Attention and speed of information processing -
Symbol coding: Timed paper-and-pencil test in
which respondent uses a key to write digits that cor-
respond to nonsense symbols. A sheet with a 9 item
key is provided, pairing digit 1–9 with a unique
symbol; below are rows of numbers with blank
squares beneath. The subject pairs each number
with its unique symbol. Measure: number of correct
number-symbol pairs completed in 90 s.
 Executive functions - Tower of London: Patients are
shown two pictures simultaneously with 3 pegs
uniquely arranged in each picture. Patients are asked
to give the number of times the balls in one picture
need to be moved in order to make the
arrangements identical on both pictures. There are
20 trials in with variable difficulty. Measure: number
of correct answers.
In addition, the Stroop task will be administered,
which measures executive functioning (verbal inhib-
ition). Patients are shown three cards on which words
are depicted in a 10 × 10 matrix. Card 1 contains color
words (red, blue, yellow and green) that are printed in
black ink in random order. Card 2 displays solid color
patches in one of these four basic colors. Card 3 again
contains color words, but these are printed in an incon-
gruous ink color. Individuals were instructed to read the
words (card 1), name the colors (card 2) and, finally,
name the ink color of the printed words (card 3) in three
subsequent sessions. Measure: reaction time and number
of errors.
Movement disorders
Patients are examined for movement disorders during
baseline, the close-out visit (at six months) and during
each follow-up visit. A standard protocol will be used, as
described by Van Harten and colleagues [62]. Patients
are barefooted and seated in a chair without armrests.
The researcher asks detailed questions about (i) use of
chewing gum or candy at the moment of assessment as
well as (ill-fitting) dentures, as both may be misdiag-
nosed as orofacial movement disorders, and (ii) subject-
ive akathisia. The patient performs different tasks to
assess the existence of movement disorders and to pro-
voke abnormal movements. Thus, the following posi-
tions are adopted in succession: resting arms on the lap
in different positions, arms hanging aside, stretching
arms, making fast alternating hand and foot movements,
opening the mouth, showing the tongue, rising from
chair, and walking. Additionally, posture, rigidity and
balance are assessed. Tongue dyskinesia is provoked by
fingertip movements, and objective akathisia by talking
conversationally while the patient is standing.
 Dyskinesia (American Psychiatric Association, 1992)
is defined as hyperkinetic choreiform involuntary
movements which often fluctuates in severity.
Tardive dyskinesia is assessed with the St. Hans
Rating Scale [35] (SHRS) and case definition is based
on Schooler and Kane criteria [63], requiring (i) the
presence of moderate dyskinesia in at least one body
area or mild dyskinesia in at least two body parts,
and (ii) the absence of other conditions resulting in
abnormal involuntary movements.
 Parkinsonism is also assessed with the SHRS [35]. A
case definition of parkinsonism is based on (i) mild
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expression of rest-tremor or rigidity as both are typ-
ical of parkinsonism, and (ii) if no tremor or rigidity
is rated, the cut-off point is one rating of moderate
or two ratings of mild on items of bradykinesia and
postural stability. The more stringent criteria for
items of bradykinesia and postural stability are
chosen as these symptoms may be part of psychi-
atric syndromes or sedation.
 Dystonia is defined as a syndrome of sustained
muscle contraction, frequently causing twisting and
repetitive movements or abnormal postures [62].
Tardive dystonia is diagnosed, following Burke’s
criteria [64], if one body area attracted a rating of at
least mild or if two or more body areas attracted a
rating of slight on the SHRS [35]. As frequent eye-
blinking (rating of ‘mild’ on the item ‘eye’) has many
causes, case definition of tardive dystonia required a
rating of at least moderate (blepharospasm) when
‘eye’ is the only symptom area.
 Akathisia [65] is defined as both subjective inner
feelings of restlessness and objective motor (leg)
movements. A case definition of akathisia is based
on a rating of at least ‘mild’ on the global akathisia
item. Akathisia is assessed with the Barnes Akathisia
Rating Scale [36] (BARS) comprising an objective
and a subjective item.
Additional measures
 Weight will be measured during each visit. In
addition, abdominal and hip circumference, height
and body mass index (BMI) will be noted. Blood
pressure and pulse will be determined. This way,
presence and severity of metabolic syndrome can be
evaluated, as defined by the American Heart
Association/National Heart, Lung and Blood
Institute [66] (AHA/NHLB).
 Medication use will be listed in a table, evaluating
type of medication, reason for use, dosage (average
dose per period), start and stop date, reason for
stopping/switching of medication.
 Use of psychoactive substances will be recorded.
Frequency, quantity of use and start date of alcohol
and cannabis will be scored. For other psychoactive
substances only frequency will be scored.
 The number of hospitalizations and relapses are also
taken from the patient’s file. Using information of
the pharmacy, the mean cumulative dose of
antipsychotic medication taken since baseline is
calculated. Relapse is defined as clinical deterioration
during at least 1 week, having consequences
(augmentation of antipsychotic dosage, hospital
admission, or more frequent consultations), reported
by the clinician and subsequently confirmed by
PANSS positive subscale item scores assessed by a
research team member, of at least one score of 5
(moderately severe) [33]. In contact with justice:
number of times is noted.
 Involuntary admission for treatment: number of
times and duration is noted.
BeHapp
General description
BeHapp is a smartphone application which is developed for
the direct day-to-day registration of several aspects of daily
life concerning the behavior of humans. The application
continuously monitors communication and exploration
patterns in patients and controls as a function of social acts,
environment social density measurements, GPS location
updates and general smartphone usage. This method cir-
cumvents the issue of subjectivity given that no active input
is required from the participant, other than installing the
application and providing some baseline information.
Methods
The application, once installed and initialized, passively
collects (meta-) data about phone call activity, bluetooth
devices and WiFi access points in the direct vicinity of
the participant, location updates and mobile application
usage. By means of integrating this data a multidimen-
sional behavioral profile of the participating individuals
can be obtained.
The application is currently only compatible with the
Android platform. Each participant will be asked if they
use an Android smartphone and if they consent to this
part of the study. After thoroughly explaining what the
application does, the participant will be provided with an
e-mail message containing instructions on how to obtain
and initialize the application. Initialization consists of en-
tering a (single-use) short-key to identify oneself to the ap-
plication, this key is also provided in the aforementioned
e-mail message. If preferred by the participant this process
can be completed with our help as well.
Privacy
Several measures are taken so as to protect the privacy
of our participants:
– As a base principle, no directly identifiable
information about any participant is stored within
any system that is part of the BeHapp service.
Participants are represented by unique id’s, which
are associated with identifiable information in
decentralised third party information systems.
– In order to decrease the attack potential (‘attack
surface’) of the BeHapp service, the publically
accessible centralised software components are
designed and implemented to work with least
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privileges and least programming logic. By this we
aim to prevent retrieval of participant data through
the application layer of our service.
– Monitoring data is encrypted before being stored
locally on the device of a participant and after each
successful upload, all of the local monitoring data is
cleared from the device. Bother measures are in
place to maximally reduce risk of revealing privacy-
sensitive information to third parties in case of loss
or theft of the smartphone.
– All communication streams between the mobile
applications and our centralized data storage
components will go through secured (encrypted)
channels using modern industry standards.
– Information gathered about identities of third
persons, e.g. contacts of participants are
obfuscated on the phone before being sent to the
central data store. Obfuscation is performed using
so called one-way-hashing / encryption techniques.
This allows the researcher to determine whether the
same instance (person or device) has been recorded
more than once while preventing them from directly
identifying the recorded instance.
– The BeHapp service resides within the Google
Cloud Platform which employs a security model
built on 15 years of experience in protecting
customer data. The platform is compliant with
HIPAA, ISO 27001 and the EU Data Protection
Directive. Furthermore, all data stored is encrypted by
default ensuring that only researchers part of the
BeHapp team are able to access the data.
– In order to reduce the attack potential (‘attack
surface’) of the BeHapp service, the publically
accessible centralised software components are
designed and implemented to work with least
privileges and least programming logic. By this we
aim to prevent retrieval of participant data through
the application layer of our service.
Duration of measurement
The duration of measurement, i.e. the time that BeHapp
actively collects and uploads data on the participant, is
variable and may depend on the specific strategy and aims
of the study it is employed in. At any time during the
course of the study you can decide to stop BeHapp from
collecting information by stopping the application in the
application manager (and re-activating it when desired) or
removing the application permanently from your device.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3822-5.
Additional file 1: Table S1. Tapering off schedules.
Additional file 2: SPIRIT checklist for the HAMLETT study.
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